

Apr 12th, 11:00 AM - 2:00 PM

Employing “FDALabel” Database to Extract Pharmacogenomics Information from FDA Drug Labeling to Advance the Study of Precision Medicine

Ryley B. Uber

Cedarville University, ryleyuber@cedarville.edu

Hong Fang

National Center for Toxicological Research

Zhichao Liu

National Center for Toxicological Research

Joshua Xu

National Center for Toxicological Research

Shraddha Thakkar

National Center for Toxicological Research

Follow this and additional works at: <http://digitalcommons.cedarville.edu/>

[research_scholarship_symposium](#)



Part of the [Other Pharmacy and Pharmaceutical Sciences Commons](#), [Pharmaceutics and Drug Design Commons](#), and the [Pharmacy Administration, Policy and Regulation Commons](#)

Uber, Ryley B.; Fang, Hong; Liu, Zhichao; Xu, Joshua; Thakkar, Shraddha; Amur, Shashi; Mummaneni, Padmaja; Chen, Minjun; Ning, Baitang; Harris, Steve; Zhou, Guangxu; Wu, Leihong; Howard, Paul; and Tong, Weida, "Employing “FDALabel” Database to Extract Pharmacogenomics Information from FDA Drug Labeling to Advance the Study of Precision Medicine" (2017). *The Research and Scholarship Symposium*. 21.

http://digitalcommons.cedarville.edu/research_scholarship_symposium/2017/poster_presentations/21

This Poster is brought to you for free and open access by DigitalCommons@Cedarville, a service of the Centennial Library. It has been accepted for inclusion in The Research and Scholarship Symposium by an authorized administrator of DigitalCommons@Cedarville. For more information, please contact digitalcommons@cedarville.edu.

Presenters

Ryley B. Uber, Hong Fang, Zhichao Liu, Joshua Xu, Shraddha Thakkar, Shashi Amur, Padmaja Mummaneni, Minjun Chen, Baitang Ning, Steve Harris, Guangxu Zhou, Leihong Wu, Paul Howard, and Weida Tong



Research & Scholarship SYMPOSIUM

Employing “FDALabel” Database to Extract Pharmacogenomics Information from FDA Drug Labeling to Advance the Study of Precision Medicine

Pharmacogenomics (PGx) focuses on how genomics and genetic variants (inherited and acquired) affect drug response. A better understanding of the association between genetic markers and individual phenotypes may improve therapy by enhancing drug efficacy, safety, and advance precision medicine. The FDALabel database (<https://rm2.scinet.fda.gov/druglabel/#simsearch-0>) was developed from the FDA's Structured Product Labeling (SPL) repository to allow users to perform full-text and customizable searches of the labeling section {e.g. Boxed Warning, Warning and Precautions, Adverse Reaction (AR) sections}. In this study, 48 known biomarkers were used to query PGx relevant contents from the FDALabel database, including Indication, Clinical Pharmacology, Clinical Studies, and Use in Specific Populations. As a result, we identified 162 drugs out of 1129 small molecule drugs with PGx biomarker information. Furthermore, statistical analysis, pattern recognition, and network visualization were applied to investigate association of drug efficacy and severe ARs with PGx biomarkers and subpopulation. The results indicated that these drugs have a higher association with certain ARs in specific patient subpopulations (e.g., a higher association between CYP2D6 poor metabolizers and ARs caused by drugs for the treatment of psychiatric disorders), and cover a broad range of therapeutic classes (e.g., Psychiatry, Cardiology, Oncology, and Endocrinology). FDALabel database (free publicly available) provides a convenient tool to navigate and extract PGx information from FDA-approved drug. The knowledge gained from these drugs and biomarkers in this study will enhance the understanding of PGx to advance precision medicine.

Ryley Uber^{1,2*}, Hong Fang^{1*}, Zhichao Liu¹, Joshua Xu¹, Shraddha Thakkar¹, Shashi Amur³, Padmaja Mummaneni³, Minjun Chen¹, Baitang Ning¹, Steve Harris¹, Guangxu Zhou¹, Leihong Wu¹, Paul Howard¹, Weida Tong¹

¹National Center for Toxicological Research, U.S. Food and Drug Administration (FDA), Jefferson, AR 72079;

²Cedarville University School of Pharmacy, Cedarville, OH, 45314

³Office of Translational Science (OTS), Center for Drug Evaluation and Research (CDER), FDA, Silver Spring, MD 20993, USA

*Equally contributed